Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: Design of the PERFORM-TAVR Trial
Canadian Journal of Cardiology · 2024-02 · 40 (2) · 267-274
DOI: 10.1016/j.cjca.2023.11.037 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Cardiology, 2024-02. Verfasst von Rosie Fountotos und 16 weiteren Autor:innen. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Frailty, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: National Institutes of Health, Canadian Institutes of Health Research.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Despite the high procedural success of transcatheter aortic valve replacement (TAVR), 2 out of 5 older adults report poor physical performance and health-related quality of life (HRQOL) in the ensuing months, particularly those with frailty. There has yet to be a trial examining the synergistic effects of exercise and protein supplementation to counteract frailty and improve patient-centred outcomes following TAVR. The PERFORM-TAVR trial is a multicentre parallel-group randomised clinical trial that is enrolling 200 frail older adults ≥ 70 years of age undergoing TAVR. Patients will be randomly allocated to 1 of 2 treatment groups: standard-of-care lifestyle education (control group) or protein-rich oral nutritional supplement for 4 weeks before TAVR with the addition of home-based supervised exercise sessions for 12 weeks after TAVR (intervention group). The primary outcome will be physical performance as measured by a blinded observer using the Short Physical Performance Battery at 3 months. Secondary outcomes at 3, 6, and 12 months will include HRQOL, as measured by the Short-Form 36 Physical and Mental Component summary scores, and a composite safety end point. The PERFORM-TAVR trial is testing a novel frailty intervention in older adults undergoing TAVR to optimise recovery and downstream HRQOL. This represents a potential paradigm shift that highlights the value of assessing and treating patients' frailty in parallel with their underlying heart valve disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03522454.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Förderung
- National Institutes of Health
- Canadian Institutes of Health Research
Zitieren
APA
Fountotos, R., Lauck, S., Piazza, N., Martucci, G., Arora, R., Asgar, A., Forcillo, J., Kouz, R., Labinaz, M., Lamy, A., Peterson, M., Wijeysundera, H., Masse, L., Ouimet, M. C., Polderman, J., Webb, J., & Afilalo, J. (2024). Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: Design of the PERFORM-TAVR Trial. Canadian Journal of Cardiology, 40(2), 267-274. https://doi.org/10.1016/j.cjca.2023.11.037
Vancouver
Fountotos R, Lauck S, Piazza N, Martucci G, Arora R, Asgar A, et al. Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: Design of the PERFORM-TAVR Trial. Canadian Journal of Cardiology. 2024;40(2):267-274. doi:10.1016/j.cjca.2023.11.037
BibTeX
@article{Fountotos2024,
author = {Fountotos, Rosie and Lauck, Sandra and Piazza, Nicolo and Martucci, Giuseppe and Arora, Rakesh and Asgar, Anita and Forcillo, Jessica and Kouz, Remi and Labinaz, Marino and Lamy, Andre and Peterson, Mark and Wijeysundera, Harindra and Masse, Lisa and Ouimet, Marie-Claude and Polderman, Jopie and Webb, John and Afilalo, Jonathan},
title = {Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: Design of the PERFORM-TAVR Trial},
journal = {Canadian Journal of Cardiology},
year = {2024},
volume = {40},
number = {2},
pages = {267--274},
doi = {10.1016/j.cjca.2023.11.037}
}
EUVIMED